Business Context and Reporting Period
Moleculin Biotech, Inc. (NASDAQ: MBRX) filed a Form 8-K on November 13, 2025, to disclose a clinical trial enrollment update under Item 7.01 Regulation FD Disclosure. The Company is developing Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed after induction therapy.
Key Financial Metrics
This filing is a current report regarding a clinical milestone and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the progress of the pivotal Phase 2B/3 "MIRACLE" study. As of November 4, 2025, 60% of the target number of subjects for the first planned interim unblinding have consented to the study. The target number for this first unblinding is 45 subjects.
Guidance, Outlook, and Risks
Management expects to complete the treatment of the first 45 subjects in the first quarter of 2026, with the initial unblinding of data to follow thereafter. Identification and recruitment are ongoing. The filing notes that the information provided is being furnished and shall not be "filed" for the purpose of the Exchange Act unless specifically identified as incorporated by reference.
Investor Verification Checklist
- Verify the exact number of subjects consented versus the 60% reported as of November 4, 2025.
- Confirm the timeline for completing treatment of the first 45 subjects in Q1 2026.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on the MIRACLE study design.
- Monitor subsequent filings for the actual date of the first interim unblinding.